{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

Acs Survey

  1. How many ACS Patients do you treat in a month? *

  2. What percentage of ACS patients fall under each of below mentioned age categories? (The total should not exceed 100%) *
    3. Age categories % Patient

  3. What percentage of ACS patients will be male and female? (The total should not exceed 100%) *
    4. Sex % Patient

  4. How frequently do you encounter patients eligible for PCI? *

  5. Out of 100 ACS patients, what percentage of patients fall under each of the below categories? (The total should not exceed 100%) *
    6. Type of ACS patient % Patient

  6. Which factors influence your decision on the reperfusion strategy? *

  7. Out of 100 patients, what percentage of patients require either of the below approach? (The total should not exceed 100%) *
    8. Type of ACS patient % Patient

  8. In which of the below categories of ACS patients do you consider using thrombolytics therapy? *

  9. Which antiplatelet agents do you commonly prescribe for ACS patients? *

  10. Have you used Ticagrelor in thrombolysed patients undergoing PCI? *

  11. If your answer to the above question is NO, then what could be the major reasons for not using Ticagrelor in thrombolysed patients undergoing PCI?

  12. In thrombolysed patients, what % of your patients receive following (The total should not exceed 100%) *
    13. Molecule % Patient

  13. In ACS Patients, what percentage of your patients receive Clopidogrel, Ticagrelor & Prasugrel (The total should not exceed 100%) *
    14. Antiplatelet drug % Patient

  14. In which Patient profile do you use Clopidogrel, Ticagrelor & Prasugrel? *
    15. Antiplatelet drug Enter Information

  15. Antiplatelet agent wise, in what percentage of patients do you prescribe more than 12 months of therapy (The total should not exceed 100%) *
    16. Antiplatelet drug % Patient

  16. Therapy Duration wise, in what percentage of patients do you prescribe Ticagrelor *
    17. Duration % Patient

  17. In which patient profile do you prescribe more than 12 months of Ticagrelor therapy? *

  18. What percentage of your patients receive the SAPT & DAPT? *
    19. Type of Therapy % Patient

  19. Which profile of patients receive SAPT? *

  20. What is your most preferred agent for SAPT? (% distribution of patients, The total should not exceed 100%) *
    21. Antiplatelet drug % Patient

  21. In your experience, which DAPT has shown the best outcomes in ACS patients? *

  22. How long do you prescribe DAPT, i.e., (P2Y12+ASP)? *

  23. What Factors influence the duration of therapy? (Rank the factor 1 to last) *
    24. Type of intervention
    Age
    Stent used
    Drugs used
    Any Others
  24. In which patient profile do you prescribe Ticagrelor 60 mg? *

  25. In what % of patients do you switch the antiplatelet treatment? *

  26. In diabetes patients with established CAD who have undergone PCI before, will you reinitiate antiplatelet? *

  27. While Selecting Brand of Ticagrelor which factors do you consider? Please rate on the scale of 1-5 (1- highest and 5- lowest) *
    28. Availability across geography
    Organization manufacturing
    Quality of product
    Personal experience with brand
    Cost
  28. Are you aware of any ongoing clinical trials investigating novel molecules or therapies for ACS? *

  29. Do you believe there is a need for awareness and education about ACS among the common public? *